AbbreviationsEuropejska umowa dot. międzynarodowego przewozu towarów niebezpiecznych, Oszacowanie toksyczności ostrej (Acute Toxicity Estimate), Chemical Abstracts Service, Classification, Labelling and Packaging (Rozp. 1272/2008), Rakotwórczość, mutagenność, toksyczność reprodukcyjna, Pochodny poziom niepowodujący zmian (Derived No-Effect Level), European Community number, Środki ochrony indywidualnej, Globalnie Zharmonizowany System (Globally Harmonized System), Międzynarodowe Zrzeszenie Transportu Lotniczego, Międzynarodowy kodeks morski towarów niebezpiecznych, Karta Charakterystyki (Safety Data Sheet), Stężenie śmiertelne 50% (Lethal Concentration), Dawka śmiertelna 50% (Lethal Dose), Najwyższe dopuszczalne stężenie (na stanowisku pracy), Chwilowe NDS, Occupational Exposure Limit, Trwałe, bioakumulacyjne i toksyczne, Przewidywane stężenie niepowodujące zmian (Predicted No-Effect Concentration), Registration, Evaluation, Authorisation and Restriction of Chemicals (Rozp. 1907/2006), Safety Data Sheet, Toksyczność narządowa (Specific Target Organ Toxicity), Substancja wzbudzająca szczególnie duże obawy (Substance of Very High Concern), Topological Polar Surface Area, Bardzo trwałe i bardzo bioakumulacyjne
Version historyv1, 28.04.2026, Pierwsza emisja. Auto-wygenerowane przez MOL-GOD v2.7.0.
Draft warning1
ReferencesPubChem, PubChem PUG REST API, https://pubchem.ncbi.nlm.nih.gov/compound/10095-06-4, Cache+consensus, Local cache (previously fetched), Local Cache, Local cache (previously fetched), ChEMBL (EBI), ChEMBL (EBI), Wikidata, wikidata, Literature, literature
References chicago[1] PE i Rada. Rozp.(WE) nr 1907/2006 (REACH). Art.31, Zał.II. Dz.Urz.UE L 396/2006., [2] Komisja Europejska. Rozp.(UE) 2020/878 — zmiana Zał.II REACH. Dz.Urz.UE L 203/2020. Od 01.01.2023., [3] PE i Rada. Rozp.(WE) 1272/2008 (CLP)+ATP 19. Dz.Urz.UE L 353/2008., [4] United Nations. GHS Rev.9. ST/SG/AC.10/30/Rev.9. ONZ, 2021., [5] ISO. ISO 7010:2019 — Graphical symbols. Safety signs., [6] ISO. ISO 3864-1:2011 — Safety colours and safety signs., [7] PubChem. PubChem PUG REST API. URL: https://pubchem.ncbi.nlm.nih.gov/compound/10095-06-4 Data: ., [8] Cache+consensus. Local cache (previously fetched). Data: ., [9] Local Cache. Local cache (previously fetched). Data: ., [10] ChEMBL (EBI). ChEMBL (EBI). Data: ., [11] Wikidata. wikidata. Data: ., [12] Literature. literature. Data: ., [13] Ustawa z 26.06.1974 r. — Kodeks pracy. Art.221–229. Dz.U. 2023 poz. 1465., [14] Rozp. MRiPS z 12.06.2018 r. — NDS/NDN. Dz.U. 2024 poz. 1017.
Literature[Adaptol--verges of possible]., Mkrtchian VR, Kozhokova LZ, 2012, Likars'ka sprava, 23534281, 0, 0, review, pubmed, 1, paywall, [Pharmacotherapy of anxiety disorders in patients with chronic cerebral ischemia]., Vorob'eva OV, Rusaya VV, 2016, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 10.17116/jnevro201611612249-54, 28300804, 0, 0, 1, https://doi.org/10.17116/jnevro201611612249-54, article, pubmed, 0.5, open, [An experience of using mebicar in patients with autonomic dysfunction associated with anxiety disorder]., Zhitkova JV, Hasanova DR, 2017, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 10.17116/jnevro201711711156-63, 29265088, 0, 0, 1, https://doi.org/10.17116/jnevro201711711156-63, article, pubmed, 0.5, open, [Clinical efficiency of combined therapy using adaptol for atopic dermatitis]., Orlov EV, Konnov PE, Arsen'eva AA, 2014, Terapevticheskii arkhiv, 25026806, 0, 0, article, pubmed, 0, paywall, [Clinical pharmacokinetics of mebikar]., Serov NV, Treskov VG, Berliand AS et al., 1984, Farmakologiia i toksikologiia, 6734814, 0, 0, article, pubmed, 0, paywall, Preventive Effect of Mebicar and Ginsenoside Rg1 on Neurobehavioral and Immunological Disruptions Caused by Intermittent Unpredictable Stress in Mice., Kim CY, Kim YG, Sin SJ et al., 2018, Neuroimmunomodulation, 10.1159/000489634, 29920498, 0, 0, article, pubmed, 0, paywall, [Adaptol in the treatment of ADHD]., Chutko LS, Surushkina SIu, Nikishena IS et al., 2009, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 19738569, 0, 0, article, pubmed, 0, paywall, TREATMENT OPTIMIZATION IN MANAGEMENT OF COMBINED PATHOLOGY - ARTERIAL HYPERTENSION AND POST-COVID SYNDROME IN ELDERLY PATIENTS., Kazakov YM, Potiazhenko MM, Nastroga TV, 2023, Wiadomosci lekarskie (Warsaw, Poland : 1960), 10.36740/WLek202307105, 37622495, 0, 0, article, pubmed, 0, paywall, [Asthenic disorders in children and their differentiated treatment]., Chutko LS, Surushkina SI, Nikishena IS et al., 2014, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 10.17116/jnevro201411412199-103, 25726788, 0, 0, clinical-trial, pubmed, 0, paywall, [Correction of psychoemotional status in patients with chronic bacterial prostatitis]., Kuz'menko VV, Kuz'menko AV, Kurnosova NV, 2012, Terapevticheskii arkhiv, 23227504, 0, 0, article, pubmed, 0, paywall
Nist linkhttps://webbook.nist.gov/cgi/cbook.cgi?ID=10095-06-4
Chembl idCHEMBL4303164
Wikidata qidQ4286560
Chemspider url
Substance typeunknown
Grok description
Cross validationDane zweryfikowane z 5 źródeł (cache, pubchem, chembl, wikidata, literature). Wykrytych konfliktów: 0.